Award Further Supports Ducommun’s Growing Missile Franchise

COSTA MESA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) a global supplier of Engineered Products, Aftermarket and Value-Added Manufacturing Solutions for the aerospace and defense industry, is proud to announce that it has been awarded an agreement from Simmonds Precision Products, Inc. (“Simmonds”) to provide electronic assemblies supporting Lockheed Martin’s (NYSE: LMT) PAC-3 family of missiles. The award, valued at over $35M, builds upon Ducommun’s existing PAC-3 missile franchise with assemblies being produced at the Company’s world-class engineering and manufacturing performance center in Tulsa, Oklahoma.

“We are honored to support our Allies and the warfighter and this follow-on award further supports the growth of our defense business as we execute our VISION 2027 Strategy,” said Stephen G. Oswald, chairman, president, and chief executive officer. “We remain focused on flawless execution, delivering for our customers and driving long-term value for shareholders.”

About Simmonds Precision Products, Inc.:

Simmonds, headquartered in Vergennes, Vermont, is a leading global designer and manufacturer of fuel & proximity sensing and structural health monitoring solutions for the aerospace and defense end markets. The Company’s products are highly engineered, proprietary components with significant aftermarket content and a strong presence across major aerospace and defense platforms.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added, innovative manufacturing solutions and products to customers in the aerospace, defense and industrial markets. Founded in 1849, the company specializes in two core areas – Electronic Systems and Structural Solutions – to produce complex products and components for commercial aircraft platforms, mission-critical military and space programs, and sophisticated industrial applications. For more information, visit Ducommun.com.

Forward-Looking Statements

This press release includes “forward looking statements” within the meaning of the federal securities laws relating to Ducommun Incorporated, including statements relating to Ducommun’s expectations pertaining to the Company’s ability to execute under agreements with its key customers and its VISION 2027 Strategy, and similar expressions that concern Ducommun’s intentions or beliefs about future occurrences, expectations, or results. Forward-looking statements are subject to risks, uncertainties and other factors that may change over time and may cause actual results to differ materially from those that are expected. It is very difficult to predict the effect of known factors, and Ducommun cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including those factors disclosed under “Risk Factors” in Ducommun’s reports filed with the SEC, including the Company’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K. The forward-looking statements included in this press release are made only as of the date of this press release, and Ducommun does not undertake any obligation to (and expressly disclaims any such obligation to) update the forward-looking statements to reflect subsequent events or circumstances.

CONTACTS:

Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665

  • TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.
  • Favorable safety profile, and generally comparable to placebo.
  • Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks.
  • Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Topline results from the final analysis set of 428 patients are presented below.

  TRUTAKNA Placebo Treatment effect p-value
Mean eGFR change from baseline at 52 weeks, mL/min/1.73m2 -0.1
(95% CI -1.4, 1.2)
-5.7
(95% CI -7.0, -4.4)
5.6
(95% CI 3.7, 7.5)
<0.0001
Annualized eGFR slope through 104 weeks, mL/min/1.73m2/year -0.6
(95% CI -1.6, 0.4)
-5.6
(95% CI -6.6, -4.6)
5.0
(95% CI 3.6, 6.5)
<0.0001
Composite kidney disease progression event through 104 weeks, n 11 38 Hazard ratio 0.24
(95% CI 0.12, 0.48)
76% risk reduction
<0.0001
Dialysis ≥30 days, transplant, or death through 104 weeks, n 0 8    

These eGFR results align with the KDIGO treatment goal to reduce the rate of kidney function decline to the physiologic rate (<1 mL/min/1.73m2/year).1 TRUTAKNA also achieved statistically significant reductions in the hierarchically tested endpoints of proteinuria, galactose-deficient IgA1 (Gd-IgA1), and hematuria. TRUTAKNA was well tolerated with a favorable safety profile generally comparable to placebo, consistent with previous results from the ORIGIN program.2 Rates of overall adverse events and infections or infestations were similar between the TRUTAKNA and placebo groups, and there were no opportunistic infections or clinically relevant hypogammaglobulinemia. Detailed results from the final efficacy analysis will be shared at an upcoming scientific congress.

“The ORIGIN 3 final analysis, demonstrating a significant reduction in risk of composite kidney disease progression, true stabilization of eGFR, and a favorable safety profile through two years, marks a milestone in IgAN treatment,” said Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Glomerular Disease Center at Stanford University Medical Center, and a principal investigator for ORIGIN 3. “Prevention of kidney failure or kidney-related death is the ultimate goal. We now have evidence suggesting that TRUTAKNA may help patients avoid dialysis, transplantation, or kidney-related death over the long term.”

“We believe that upstream inhibition of BAFF and APRIL with TRUTAKNA achieves results that reflect the potential for comprehensive disease modification in IgAN. ORIGIN 3 is the first reported Phase 3 IgAN trial to reach alignment with the FDA on an earlier final efficacy analysis, offering patients randomized to placebo an earlier opportunity to transition to open-label TRUTAKNA. The final results support this alignment and we plan to submit the supplemental BLA in the fourth quarter of this year. We look forward to the potential full approval of TRUTAKNA in 2027,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We reiterate our gratitude to the patients, investigators, employees, and collaborators who have helped us to deliver a transformative therapy to patients in need.”

“We are excited for the upcoming supplemental BLA submission based on the ORIGIN 3 final analysis. Since receiving accelerated approval, we have seen significant interest from the IgAN community. In the first ten weeks, we have generated over 350 patient start forms. We are seeing paid claims and are pleased with initial payer policies. The early momentum of the TRUTAKNA launch is very encouraging,” said Matt Skelton, Chief Commercial Officer of Vera Therapeutics.

About IgAN

IgAN is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney disease and kidney failure worldwide.3,4 Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between 30 and 40 years of age.5,6 Over time, IgAN can lead to irreversible kidney damage and may ultimately require dialysis or kidney transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.4

About TRUTAKNA (atacicept-vymj)

TRUTAKNA, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL.7 BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology. In IgAN, activated B cells produce both the antigen and associated antibodies that result in the production of damaging IgA immune complexes. The overlapping roles of BAFF and APRIL in activating B cells support the potential for TRUTAKNA as a disease-modifying therapy.3 TRUTAKNA is self-administered as an at-home, small-volume (1 ml), 150 mg once-weekly autoinjector.

Indication

TRUTAKNA (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Important Safety Information

Contraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.

Warnings and Precautions

Immunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.

The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.

Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).

Use in Specific Populations

Pregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.

Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see full Prescribing Information for additional Important Safety Information.

TRUTAKNA TRU SUPPORT™ Patient Support Program

We are dedicated to ensuring that eligible IgAN patients can access the first approved therapy that targets both BAFF and APRIL. TRUTAKNA TRU SUPPORT, our patient support program, offers insurance coverage assistance, financial assistance options for eligible patients, and educational resources designed to support patient access and care. Eligible commercially insured patients may pay as little as $0 out of pocket through our copay assistance program. More information will be available on www.veratx.com.

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability of TRUTAKNA to stabilize eGFR and prevent kidney disease progression; the strength of Vera Therapeutics’ commercial launch momentum for TRUTAKNA; the plan to submit a supplemental BLA to the FDA in the fourth quarter of 2026 for full approval; the timing for the detailed results from the final efficacy analysis to be shared at an upcoming scientific congress; the ability of the ORIGIN 3 final analysis to mark a milestone in IgAN treatment; the ability for the upstream inhibition of BAFF and APRIL with TRUTAKNA to achieve results that reflect comprehensive disease modification in IgAN; the ability of TRUTAKNA to help patients avoid dialysis, transplantation, or kidney-related death over the long term; the potential for the FDA to grant full approval to TRUTAKNA and the timing of such approval; the interest the IgAN community has in TRUTAKNA; the potential success of the TRUTAKNA launch; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

References
1. Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
2. Lafayette R, Barbour SJ, Brenner RM, et al. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N Engl J Med. 2026;394(7):647-657. doi:10.1056/NEJMoa2510198
3. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. Published 2024 Feb 1. doi:10.3389/fneph.2023.1346769
4. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135
5. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665
6. Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol. 2019;30(5):866-876. doi:10.1681/ASN.2018101017
7. TRUTAKNA™ [Prescribing Information]. Brisbane, CA: Vera Therapeutics, Inc; July 2026

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

14 Year Mine Life with an After-Tax NPV5% of US$1.05 Billion

All dollar amounts are in USD unless otherwise indicated

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce an updated Life-of-Mine plan for its recently acquired Casa Berardi gold mine, located in Quebec, Canada.

Casa Berardi Life-of-Mine Plan Highlights

  • 14-year mine life (2027-2040) with 1,630,000 ounces of total gold production
  • Life-of-Mine average annual gold production of 116,000 ounces at AISC1 of $1,877 per ounce
  • Years 2030-2038 average annual gold production of 132,000 ounces at AISC of $1,776 per ounce
  • After-tax NPV5%2 of $1.05 billion at Base Case consensus gold prices3
  • After-tax NPV5% increases to $1.43 billion at $4,350 per ounce spot gold price4
  • Orezone has reinitiated exploration at Casa Berardi, currently ramping-up drilling to 100,000 metres per annum. Multiple actionable exploration fronts, with clear opportunity to increase underground grades, expand production and further reduce costs

Patrick Downey, President and CEO, commented “The release of the Casa Berardi Life-of-Mine plan is a significant milestone for Orezone. The result of the Life-of-Mine plan clearly underscores the opportunity and value proposition identified by Orezone in acquiring the Casa Berardi Mine. Its transformational acquisition positions the Company as an established multi-asset producer, with a significant and fully funded growth profile.

The Life-of-Mine plan highlights a robust 14-year mine life, with average annual production of 116,000 ounces at an All-In Sustaining Cost (“AISC”) of US$1,877 per ounce. The initial years of the plan are marked by a ramp-up phase, with investments in new equipment, underground development and open pit waste stripping, supporting an increase in average annual production to a sustained 132,000 ounces. The Company views this Life-of-Mine plan as an excellent baseline, which with ongoing optimization and exploration, we fully expect to further increase the production profile and lower costs.

This upside potential has already been well demonstrated, with the Casa Berardi mill continuously operating at rates above that assumed in the Life-of-Mine plan, and initial exploration results highlighting the near-term potential to delineate higher-grade underground zones of near-surface mineralization.

The Casa Berardi Life-of-Mine plan also marks an important milestone in Orezone’s expansion into Quebec, the foundation of which is the support of our dedicated employees, community partners and First Nations. The Company looks to continue this momentum with the release of a PEA study on its Heva-Hosco development project, located along the prolific Cadillac Larder-Lake Break in Quebec, in the fourth quarter.”

Table 1 - Casa Berardi Life of Mine Plan Summary

Figure 1 - Casa Berardi Production and AISC Profile

Mineral Resource Statement

The updated Casa Berardi mineral resource estimates have an effective date of June 30, 2026. The mineral resource excludes material mined up to the effective date, as well as excluding stockpiles.

Table 2 - Casa Berardi Mineral Resource

Mine Plan and Production Overview

The Casa Berardi Life-of-Mine plan comprises 14 years of continuous operations from 2027 to 2040, producing a total of 1,630,000 ounces of gold. Mining will be conducted via both underground and open pit, with ore processed at the Casa Berardi mill. The Casa Berardi Life-of-Mine plan includes Inferred Mineral Resources, and as such is classified as a Preliminary Economic Assessment (“PEA”)6. No mineral reserves are defined for Casa Berardi. The mine plan was completed by BBA Consultants under guidance from Orezone. The open pit and underground mine plans were evaluated using DeswikTM algorithms to create optimal mineable shapes based on economic and technical input parameters including mine dilution and recovery. Underground stope design parameters were based on current operating experience, with stopes that were uneconomic due to distance from infrastructure excluded from the Life-of-Mine plan.

Figure 2 - Underground and Open Pit Production Profile

Underground Mining

Casa Berardi has a long history of underground mining, dating back to the late 1980s. In recent years, mine planning by the previous operator prioritized a shift to open pit operations, resulting in a sharp decrease in investment in underground development, equipment and exploration. Orezone’s Life-of-Mine plan is centered on re-establishing historical underground production rates at Casa Berardi, which based on the current mineral resource and sustained investment, supports a 12-year underground mine life.

The underground mine plan is based on continuous operations at the currently active West Mine (2027-2038), with the past producing East Mine re-commencing operations within three years (2029-2038). Underground mining practices are well established at Casa Berardi, using conventional underground equipment and long-hole open stoping methods.   Mining at Casa Berardi is owner-operated, with a mining contractor recently mobilized to increase lateral development rates.

Several new pieces of underground mining equipment have recently been delivered to site, with the staged procurement of new equipment continuing through 2029 as underground mining rates are increased.

The West Mine is accessed via a hoist or a ramp down to the 1,080m level, with ore brought to surface and transported 5 kilometres to the Casa Berardi mill utilizing 60t trucks. Access to the East Mine is provided by a separate ramp, collared near the Casa Berardi mill, which has been developed down to the 730m level. Active mining in the East Mine ceased in 2023 and work has now commenced on the re-opening of the East Mine access and ramp in anticipation of re-commencement of operations in 2029.

Open Pit Mining

Mining is carried out using conventional drill, blast, load and haul surface mining methods, with an owner-operated fleet. A stockpiling strategy is employed to prioritize delivery of the highest-grade ore to the mill, with stockpiles developed to maintain consistent mill throughput during waste stripping phases.

The Life-of-Mine plan comprises four separate open pits. The current F160 pit phase is scheduled to be complete at the end of 2026, with open pit production shifting to the F134 pit for 2027 and 2028. The F160 pit expansion waste cutback is scheduled to commence in late 2027, with ore mining from the F160 pit to resume in late 2028 and continue through to 2031. The Principal (2031-2038) and WMCP (2034-2040) pits will be mined thereafter.

The F134 Phase 1 pit is permitted, with the Phase 2 permit amendment to be submitted in the fourth quarter. The F160 pit expansion will require a permit amendment, which will be submitted in the fourth quarter as well. The Principal and WMCP pits, and associated surface infrastructure, will be subject to further permitting requirements. This work has commenced and will be advanced over the coming years.

Processing

The Casa Berardi processing facility has a nameplate capacity of 3,730tpd. Run-of-mine ore is processed using a conventional single stage primary crusher followed by a two-stage SAG and ball mill grinding circuit, gravity circuit, and CIL circuit, producing gold doré. Life-of-mine average annual projected gold recoveries range from 80% to 88% for underground material and from 77% to 91% for open pit material.

Approximately 15-20% of the Casa Berardi tailings are used in the mine backfill cycle. Tailings that are not used for mine backfill are disposed of at the tailings storage facility (“TSF”). The current TSF design will support tailings deposition until 2031, after which the exhausted F134 and F160 pits will be utilized for in-pit tailings deposition. The F160 pit will host multiple years of excess tailings capacity beyond the current Life-of-Mine plan.

Figure 3 - Casa Berardi Long Section Showing Open Pits and Planned Underground Stoping Zones

Table 3 - Casa Berardi Life-of-Mine Schedule

Gold Price Sensitivity

Table 4 - After-Tax Gold Price Sensitivity

Enhancement Opportunities

Casa Berardi hosts multiple opportunities to further expand the mine’s production profile and lower costs, including:

  • Mineral Resource Expansion: The Casa Berardi mineral resource remains open for expansion on multiple fronts, including (1) opportunities to upgrade the resource category of multiple mineralized lenses within the Life-of-Mine plan, (2) the expansion of current underground ore zones that remain open at depth, and (3) the development and growth of new underground zones including the down-plunge continuation of the F134 and F160 zones beneath the open pits. In addition, drill results disclosed in the May 19, 2026 news release, as well as all drilling executed since then, are not included in the resource estimate supporting the Life-of-Mine-plan.
  • New Zone Discovery: In recent years, resource growth at Casa Berardi has largely been the product of incremental step-out drilling from known zones of mineralization. Given the significant exploration and mining datasets dating back to the 1980’s at Casa Berardi, Orezone is developing the first comprehensive mineral system model supporting the identification and ranking of prospective exploration targets in the near-mine area and beyond. With reference to the south side of the Casa Berardi Fault which has been mined underground to depths of approximately 1,170m, the north side of the fault has seen limited exploration drilling, specifically at depth. Hosting a proven gold-bearing hydrothermal system and ore zones currently being mined by open pit, the north side is considered to be highly prospective and represents a key area for exploration in years to come.
  • Higher Grades: With an established 12-year underground mine life, Orezone’s key exploration focus is to re-establish high-grade underground stope inventory. Supported by sustained exploration and underground development between 2006-2016, the West Mine historically achieved an average annual production of approximately 141,000 ounces at a head grade of approximately 7.0 g/t. Exploration drilling ramping up to a sustained 100,000 metres per annum in upcoming years will provide opportunities for high-grade discoveries, with the goal of sequencing higher grade ounces into the front end of the mine plan, further increasing the production profile and lowering the AISC.
  • Regional Exploration: The Casa Berardi exploration tenements are centered on 37 kilometres of strike along the Casa Berardi Fault Zone, which to date has seen limited systematic exploration. As with the Cadillac Larder-Lake and the Destor-Porcupine Fault Zones to the south which host multiple operating mines along comparable strike lengths, the Casa Berardi property has the potential to host several other gold deposits.
  • Increased Mill Throughput: The Life-of-Mine study assumes a mill throughput rate of 3,835tpd. Since acquiring the Casa Berardi Mine, Orezone has optimized the average mill throughput to approximately 4,025tpd, and has achieved daily rates of up to 4,775tpd. Higher achieved mill throughput moving forward presents the opportunity to realize incrementally higher annual gold production than that detailed in the Life-of-Mine plan.
  • Optimization: Key areas of focus to further optimize operations include:
    • Open Pit Grade Control: Implementation of open pit grade control drilling presents the opportunity to reduce external dilution and incrementally increase head grades by further constraining ore and waste dig polygons. Additional benefits include further mill feed flexibility with additional ore grade bins, and overall improved reconciliation.
    • Improved Gold Recoveries: Opportunities to improve gold recoveries include additional metallurgical domaining studies to optimize the material feed blend to the mill, as well as further plant optimizations, including upgrading the mill process control system to current industry standards.
    • Updated Recovery Curves: The metallurgical grade recovery curves at Casa Berardi were developed when the mine was operating at a higher head grade, with the current lower grade extrapolations yielding lower recoveries than actuals. Updating the grade recovery curves for the lower grade profile outlined in the early years of the Life-of-Mine plan provides upside potential to that currently being assumed.

Technical Report Filing

The National Instrument 43-101 Technical Report supporting the Casa Berardi Life-of-Mine plan and the Mineral Resource Estimates will be filed on SEDAR+ within 45 days of this news release.

About Orezone Gold Corporation

Orezone Gold is an emerging intermediate gold producer with operations in Canada and West Africa. Its Casa Berardi and Bomboré gold mines host significant mineral endowments, growth opportunities, and exploration upside. The recently acquired Casa Berardi mine in Quebec has produced over 3.2 million ounces of gold to date while the Bomboré mine was constructed and brought into production by Orezone in late 2022.

Orezone is led by an experienced management team committed to safe, sustainable, and responsible mining practices, with a focus on delivering long-term value for all stakeholders.

Contact Information

Patrick Downey
President and Chief Executive Officer

Amanda Mallough
Vice President, Investor Relations

Tel: 1 778 945 8977
info@orezone.com / www.orezone.com

For further information please contact Orezone at +1 (778) 945-8977 or visit the Company’s website at www.orezone.com.

The Toronto Stock Exchange neither approves nor disapproves the information contained in this news release.

This announcement was authorized for release by Patrick Downey, Director, President & CEO.

Notes For Casa Berardi Mineral Resource Estimate

  1. The Qualified Persons for the Mineral Resource Estimate, as defined by National Instrument 43-101, is Alexandre Nickerson, P.Eng. The effective date of the Mineral Resource Estimate is June 30, 2026.
  2. Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability. The Mineral Resource Estimate follows CIM 2014 Definition Standards for Mineral Resources and Mineral Reserves.
  3. Open-pit Mineral Resources are reported within conceptual pit shells at cut-off grades varying between 0.63 g/t and 0.82 g/t Au. The cut-off grades were calculated using a gold price of $4,000/oz, a USD/CAD exchange rate of 1.35, and mining cost averaging $3.11/t across the pits.
  4. Underground Mineral Resources are reported within mineable shapes created using cut-off grades ranging between 2.70 g/t Au to 3.33 g/t Au. The cut-off grades were calculated using a gold price of $3,000/oz, a USD/CAD exchange rate of 1.35, and mining cost varying from $213.00/t to $244.00/t.
  5. Numbers may not add up due to rounding

Non-IFRS Measures

The Company has included certain performance measures in this news release that are commonly used in the mining industry but are not defined under IFRS, including “AISC” and “free cash flow”. Non-IFRS measures do not have any standardized meaning prescribed under IFRS, and therefore, they may not be comparable to similar measures presented by other companies. The Company uses such measures to provide additional information, and they should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

A reconciliation of the non-IFRS measures used herein can be found in the Company’s most recently filed Management’s Discussion and Analysis dated August 12, 2026, which is available on SEDAR+ (www.sedarplus.ca and on the Company’s website at www.orezone.com.

Qualified Persons

The Casa Berardi Life-of-Mine plan was prepared under the supervision of Rob Henderson, P.Eng., Vice President, Technical Services of Orezone and Alexandre Nickerson, P.Eng., Geology Superintendent of Orezone Quebec Inc., each of whom is a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Henderson and Mr. Nickerson have reviewed and approved the scientific and technical information contained in this news release and have verified the data underlying the information for which they are responsible. Their verification included a review of the underlying geological, sampling, analytical, metallurgical, mining and economic data and assumptions used in preparing the Life-of-Mine plan. No limitations were imposed on their verification processes. Neither Mr. Henderson nor Mr. Nickerson is independent of the Company within the meaning of NI 43-101.

Competent Persons

In accordance with ASX Listing Rule 5.12, Rob Henderson, P.Eng., and Alexandre Nickerson, P.Eng., confirm that the information in this announcement relating to the Casa Berardi Life-of-Mine plan is an accurate representation of the available data and supporting documentation for the project. Mr. Henderson is a member of Professional Engineers Ontario and has over 35 years of relevant experience. Mr. Nickerson is a member of the Ordre des ingénieurs du Québec and has more than seven years of relevant experience. Each has sufficient experience relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person, as defined in the JORC Code. Mr. Henderson is Vice President, Technical Services of Orezone, and Mr. Nickerson is Geology Superintendent of Orezone Quebec Inc. Each is a full-time employee of the applicable company and consents to the inclusion in this announcement of the matters based on his information in the form and context in which they appear.

Cautionary Note Regarding Forward Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements”) within the meaning of the securities laws of applicable jurisdictions. Forward looking statements are generally identified by words such as “anticipate”, “believe”, “expect”, “intend”, “estimate”, “forecast”, “plan”, “potential”, “project”, “target”, “will”, “would”, “could”, “should” and similar expressions.

Forward looking statements in this news release include, but are not limited to, statements regarding: the Casa Berardi Life-of-Mine plan, including the anticipated mine life, production profile, gold production, head grades, recovery rates, throughput, mining rates, operating costs, AISC, capital expenditures, cash flows and net present value; the timing and sequencing of underground and open pit mining; the re-establishment of historical underground production rates; the continuation of operations at the West Mine and the recommencement of operations at the East Mine; planned underground development, waste stripping, equipment purchases and contractor activities; the timing and receipt of required permits and approvals, including those relating to the F134 and F160 pits and the Principal and WMCP pits and associated infrastructure; the capacity and future use of the tailings storage facility and exhausted open pits for tailings deposition; the potential benefits of operational improvements, increased mill throughput, improved recoveries and grade control; the timing, scope and results of exploration and drilling programs, including the planned ramp-up to 100,000 metres of drilling annually; the potential to expand mineral resources, discover new zones, delineate higher-grade underground mineralization, add mineralized material to future mine plans, increase production and reduce costs; and the timing of the preliminary economic assessment for Heva-Hosco.

Forward looking statements are based on assumptions that management considers reasonable as of the date of this news release, including assumptions regarding: the accuracy of mineral resource estimates and the geological, metallurgical and technical interpretations on which they are based; the availability, continuity, grade and recoverability of mineralized material; the successful execution of the Life-of-Mine plan; gold prices, exchange rates and other economic assumptions described in this news release; operating and capital costs; equipment, labour, supplies, services and financing being available on acceptable terms; the performance of contractors and suppliers; the receipt and maintenance of all required permits and approvals within the expected timelines; the ability to maintain anticipated mining and processing rates; and the absence of material adverse changes in applicable laws, market conditions or the operating environment.

Forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. These risks include, but are not limited to: the inherent uncertainty of mineral resource estimates and mine plans, particularly where the Life-of-Mine plan includes Inferred Mineral Resources that are considered too geologically speculative to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves; the risk that Mineral Resources may not be converted to Mineral Reserves; variations in ore grade, tonnage, recovery, throughput and production; changes in gold prices, exchange rates, inflation, capital and operating costs; delays or failures in underground development, waste stripping, equipment delivery, construction, permitting or regulatory approvals; geotechnical, hydrological, metallurgical and environmental risks; tailings management risks; equipment failures, accidents, labour disputes and shortages of personnel, equipment or supplies; the results of exploration and drilling programs differing from expectations; the availability and cost of financing; changes in laws and regulatory requirements; and the other risks described in the Company’s most recent annual information form and management’s discussion and analysis filed under the Company’s profile on SEDAR+.

Although the Company believes that the assumptions and expectations reflected in the forward looking statements are reasonable, there can be no assurance that such statements will prove to be accurate. Readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements are made as of the date of this news release, and the Company disclaims any obligation to update or revise them to reflect new events or circumstances, except as required by applicable law.

1 Non-IFRS measure. See “Non-IFRS Measures” for an explanation of these financial measures.
2 Includes the impact of the Franco-Nevada Corporation (“FNV”) gold stream. FNV is entitled to fixed gold deliveries of 6,500 ounces per annum between 2027 to 2030 followed by variable deliveries equal of 5% of gold production in subsequent years. The Company receives 20% of the spot gold price for each ounce delivered.
3 Base Case gold price assumptions based on September 2026 consensus pricing.
4 Spot gold price assumption based on September 11, 2026 closing price.
5 Non-IFRS measure. See “Non-IFRS Measures” for an explanation of these financial measures.
6 The Casa Berardi Life-of-Mine plan is preliminary in nature, it includes Inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the Life-of-Mine plan will be realized. The Casa Berardi Life-of-Mine plan supersedes the prior technical report for Casa Berardi and should not be considered together with or as an update to any prior economic analysis.  

Infographics accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/7a48a2e0-86dd-4f31-8112-118cd05ab22d

https://www.globenewswire.com/NewsRoom/AttachmentNg/e84b5bba-4919-4903-981a-6789133ce91d

https://www.globenewswire.com/NewsRoom/AttachmentNg/c6a40eaa-fee5-42ce-8903-c623ffeccade

https://www.globenewswire.com/NewsRoom/AttachmentNg/1396afb1-ad19-4602-826f-d865c6b5dd79

https://www.globenewswire.com/NewsRoom/AttachmentNg/49afd4c4-155f-418e-9c2d-0e4c263f04d1

https://www.globenewswire.com/NewsRoom/AttachmentNg/b578a4e8-6c58-4ad0-88d5-480f446fcc5c

https://www.globenewswire.com/NewsRoom/AttachmentNg/da12dcee-d3c1-4f79-8008-e6ea51cbd751

ZUG, Switzerland, Sept. 15, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company“) (TSX: LAR) (NYSE: LAR) today announced the closing of the $180 million strategic investment from Ganfeng Lithium Group Co., Ltd. (“Ganfeng”) through the issuance of a six-year unsecured convertible note (the “Note” or the “Strategic Investment”).

Sam Pigott, the Company’s CEO, commented: “With the funds from the Strategic Investment and cash distributions from Cauchari-Olaroz, Lithium Argentina now has a materially stronger balance sheet, with lower net debt, a six-year maturity profile and a low cost of capital. That combination gives us the flexibility to advance Stage 2 at Cauchari-Olaroz and support PPG in a disciplined, phased approach that limits equity dilution and unlocks the value of both assets for our shareholders.”

The Note bears a coupon of 4.0% per annum, matures six years from issuance and is convertible into common shares of the Company at $12.50 per share, on the terms described in the Company’s news release dated August 24, 2026. Net proceeds, together with cash on hand, will be used to repay in full the Company’s $259 million convertible notes due January 2027. The Company’s joint venture with Ganfeng in respect of the consolidation of the Pozuelos-Pastos Grandes project (“PPG”) remains on track to be completed by the end of September 2026.

Ganfeng currently owns approximately 9.6% of the Company’s issued and outstanding common shares. Assuming full conversion, Ganfeng would receive 14.4 million additional common shares and would own approximately 16.1% of the Company’s common shares on a fully diluted basis.

ABOUT LITHIUM ARGENTINA

Lithium Argentina is a producer of lithium carbonate for use primarily in lithium-ion batteries and electric vehicles. The Company, in partnership with Ganfeng, operates the Cauchari-Olaroz lithium brine operation in the Jujuy province of Argentina and is advancing PPG in the Salta province of Argentina. Lithium Argentina currently trades on the TSX and on the NYSE under the ticker “LAR”.

For further information contact:
Investor Relations
Telephone: +1 778-653-8092
Email: kelly.obrien@lithium-argentina.com
Website: http://www.lithium-argentina.com

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (which we refer to collectively as forward-looking information) under the provisions of applicable securities legislation. Forward-looking information can be identified by the use of words such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “propose”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe”, “scheduled”, “implement” and similar words or expressions. All statements, other than statements of historical fact, are forward-looking information. Forward-looking information in this news release include, without limitation, information with respect to the following matters or the Company’s expectations relating to such matters:  the anticipated benefits of PPG and the Strategic Investment; the expected use of proceeds from the Strategic Investment, together with cash on hand, to repay, in full, the convertible notes due January 2027, and the anticipated benefits therefrom; the anticipated shareholdings of Ganfeng in the Company following conversion of the Note; the Company’s plans and next steps to advance PPG; the Company’s plans to advance the Stage 2 expansion at Cauchari-Olaroz and to support PPG, including the timing and phasing thereof and the anticipated benefits therefrom; and the Company’s balance sheet, net debt, maturity profile and cost of capital and the anticipated flexibility therefrom; and the expected timing of closing of the PPG joint venture.

Forward-looking information may involve known and unknown risks, assumptions and uncertainties which may cause the Company’s actual results or performance to differ materially. This information reflects the Company’s current views with respect to future events and is necessarily based upon a number of assumptions that, while considered reasonable by the Company today, are inherently subject to significant uncertainties and contingencies, and accordingly, the Company can give no assurance that these assumptions and expectations will prove to be correct. With respect to forward-looking information included in this news release, the Company has made assumptions regarding, among other things: current technological trends; the business relationship between the Company and Ganfeng; ability to fund its operations; the ability to operate in a safe and effective manner; uncertainties relating to obtaining and/or maintaining mining, exploration, development, environmental and other permits or approvals in Argentina; demand for lithium; impact of increasing competition in the lithium business, including the Company’s competitive position in the industry; general economic conditions; stability and support of legislative, regulatory and community environment in the jurisdiction where it operates; estimates of and changes to market prices for lithium and commodities; estimates costs for the project or operation; estimates of mineral resources and mineral reserves, including whether mineral resources will ever be developed into mineral reserves; reliability of technical data; and the ability to achieve full production; and accuracy of budget and estimates. Forward-looking information also involves known and unknown risks that may cause actual results to differ materially, these risks include, among others: the anticipated benefits of PPG and the Strategic Investment may not be realized as contemplated, or at all; the Company may not be able to use proceeds from the Strategic Investment, together with cash on hand, or realize the benefits from the intended use, as contemplated, or at all;; the Company may not be able to complete the financing process for PPG as contemplated, or at all; the Company’s plans for PPG and PPG may not be implemented as contemplated, or at all; the Company’s plans and next steps to advance PPG may not be implemented as contemplated, or at all; the benefits from the Company’s advancement of PPG may not be realized as anticipated, or at all; the benefits of RIGI may not be realized as anticipated, or at all; the operations may not operate and produce as planned; cost overruns; market prices affecting development of the operation; risks associated with co-ownership arrangements; risks with ability to successfully secure adequate financing if necessary; risks to the growth of the lithium markets; lithium prices; inability to obtain any future required governmental permits and that operations may be limited by government-imposed limitations; technology, cyber security and artificial intelligence risk; inability to achieve and manage expected growth; political risk associated with foreign operations, including co-ownership arrangements with foreign domiciled partners; emerging and developing market risks; operational risks; changes in government regulations; changes in environmental requirements; failure to obtain or maintain necessary licenses, permits or approvals; insurance risk; receipt and security of mineral property titles and mineral tenure risk; changes in project or operation parameters; uncertainties associated with estimating mineral resources and mineral reserves, including uncertainties regarding assumptions underlying such estimates; whether mineral resources will ever be converted into mineral reserves; opposition to the Company’s projects; geological or technical or processing problems; liabilities and risks; health and safety risks; unanticipated results; unpredictable weather; unanticipated delays; reduction in demand for lithium; inability to generate profitable operations; restrictive covenants in debt instruments; intellectual property risks; dependency on key personnel; currency and interest rate fluctuations; and volatility in general market and industry conditions. Additional risks, assumptions and other factors are set out in the Company’s management discussion analysis and most recent Annual Report on Form 20-F, copies of which are available on SEDAR+ at www.sedarplus.ca

Although the Company has attempted to identify important risks and assumptions, given the inherent uncertainties in such forward-looking information, there may be other factors that cause results to differ materially. Forward-looking information is made as of the date hereof and the Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. 

Transaction in Own Shares

September 14, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 14 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
14/09/2026 400,000 £ 36.1200 £ 35.7250 £ 35.9741 LSE GBP
14/09/2026 – – – – Chi-X (CXE) GBP
14/09/2026 – – – – BATS (BXE) GBP
14/09/2026 200,000 € 42.2800 € 41.8350 € 42.1040 XAMS EUR
14/09/2026 – – – – CBOE DXE EUR
14/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

 

Attachment

15-Game Regular Season Package Simulcasts on WOIO, WUAB and Rock Entertainment Sports Network Alongside Cavaliers on DAZN Subscription Platform

ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) — Gray Media and the Cleveland Cavaliers today announced a historic partnership with DAZN to broadcast 15 regular season Cavaliers games completely free, over-the-air during the 2026-27 NBA season.   The 15-game package is a simulcast of the games available for free in front of the Cavaliers on DAZN paid subscription paywall offering.

The games will air locally in Cleveland on Gray Media’s stations, WOIO (CBS 19) and WUAB (MyNet 43), and statewide on Rock Entertainment Sports Network, giving fans unprecedented access to one of the NBA’s premier teams.   Rock Entertainment Sports Network is a collaboration between Gray Media and Rock Entertainment Group, which owns the Cleveland Cavaliers, Cleveland Sirens, Cleveland Monsters, and Cleveland Charge.
        
In addition, Gray stations in other markets, including Cincinnati, Ohio; Lima, Ohio; and Parkersburg, West Virginia will also air the 15-game package.   Gray will seek additional third-party broadcasters to air the games in other parts of the territory where Gray does not own or operate television stations.

“We are absolutely thrilled to partner with the Cavaliers and DAZN to bring world-class basketball straight to our viewers’ living rooms completely free of charge,” said Chris Conroy, General Manager of WOIO/WUAB.   “Local sports belong on local television, and this historic agreement delivers for Cavs fans.”

WUAB’s deep sports pedigree includes a long history of broadcasting Cavaliers games and a nostalgic legacy of carrying Cleveland Indians baseball.   Adding live Cleveland Cavaliers basketball to a powerhouse lineup that has featured the Cleveland Browns, Columbus Blue Jackets hockey, college football, NCAA March Madness, and legendary events like The Masters, WOIO and WUAB continue to serve as the undisputed home of free, live Cleveland sports.

“In partnership with Gray and DAZN, we’ve built the most enhanced and accessible broadcast ecosystem we’ve had in years,” said Nic Barlage, CEO of Rock Entertainment Group, Cleveland Cavaliers and Rocket Arena. “Our fans are at the core of every decision we make, and this season we’re proud to triple the number of games available for free, over-the-air on Gray’s local stations and Rock Entertainment Sports Network.”
“This partnership represents a forward-thinking approach to serving local sports fans,” added Matt Moran, Senior Operating Officer for Gray Media. “Combined with our deep in-season coverage on Rock Entertainment Sports Network, we are proud to expand our collaboration with the Cavaliers and DAZN to deliver premium, live sports content directly to the best fans in the country.”

The current schedule is provided below and is subject to change.   Check local listings for details.   The broadcast schedule will include pregame and postgame coverage.

  • Mon. October 26, 2026 – Minnesota at Cleveland 7:00 PM (WUAB)
  • Thur. October 29, 2026 – Cleveland at Atlanta 7:00 PM (WUAB)
  • Mon. November 2, 2026 – Oklahoma City at Cleveland 7:00 PM (WOIO-CBS)
  • Sat. November 14, 2026 – Dallas at Cleveland 7:30 PM (WOIO-CBS)
  • Sat. December 12, 2026 – Golden State at Cleveland 8:00 PM (WOIO-CBS)
  • Fri. December 18, 2026 – Cleveland at Detroit 7:30 PM (WOIO-CBS)
  • Wed. December 23, 2026 – Cleveland at Washington 7:00 PM (WOIO-CBS)
  • Sat. January 2, 2027 – Cleveland at Charlotte 1:00 PM (WOIO-CBS)
  • Sat. January 23, 2027 – Cleveland at Dallas 8:00 PM (WOIO-CBS)
  • Fri. January 29, 2027 – Cleveland at Toronto 7:00 PM (WOIO-CBS)
  • Sat. February 6, 2027 – Orlando at Cleveland 7:30 PM (WOIO-CBS)
  • Sun. February 14, 2027 – Phoenix at Cleveland 1:00 PM (WOIO-CBS)
  • Tue. March 9, 2027 – Cleveland at Detroit 8:00 PM (WOIO-CBS or WUAB)
  • Sun. March 14, 2027 – Cleveland at Sacramento 6:00 PM (WOIO-CBS or WUAB)
  • Sun. April 4, 2027 – Charlotte at Cleveland 3:00 PM (WOIO-CBS or WUAB)

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets.   We serve 117 full-power television markets that collectively reach approximately 37% of US television households.   The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025.   We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services.   Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

About Cleveland Cavaliers:

The Cleveland Cavaliers, founded in 1970, are a professional basketball team in the NBA’s Eastern Conference that plays at Rocket Arena in downtown Cleveland, Ohio.   The Cavaliers won the NBA Championship in 2016 and took the Eastern Conference crown in 2007, 2015, 2016, 2017 and 2018.   The Cavaliers were awarded the 2025 NBA Team of the Year and also the recipient of the league’s Inclusion Leadership Award.   The Cavaliers are a part of Rock Entertainment Group, the umbrella entity for the sports and entertainment properties under Cavaliers Chairman Dan Gilbert’s ROCK Family of Companies.   Nic Barlage serves as the CEO of the Cavaliers, Rocket Arena, and Rock Entertainment Group.   The team is led by President of Basketball Operations Koby Altman and Head Coach Kenny Atkinson.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

Cleveland Cavaliers Contact:

Zachary Abaie, Vice President, Corporate Communications, zabaie@cavs.com, 216-559-0199

         #       #         #

STEINHAUSEN, Switzerland, Sept. 15, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced that the Deepwater Conqueror was awarded a two-well contract for work in Equatorial Guinea with an undisclosed operator. The estimated 170-day campaign is expected to commence in 2027 in direct continuation of the rig’s current contract in the U.S Gulf and contribute approximately $80 million in backlog, excluding additional services and compensation for mobilization and demobilization.

About Transocean

Transocean is a leading international provider of offshore contract drilling services for oil and gas wells. The Company specializes in technically demanding sectors of the global offshore drilling business with a particular focus on ultra-deepwater and harsh environment drilling services and operates the highest specification floating offshore drilling fleet in the world.

Transocean owns or has partial ownership interests in and operates a fleet of 27 mobile offshore drilling units, consisting of 20 ultra-deepwater floaters and seven harsh environment floaters.

Forward-Looking Statements

The statements described herein that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements could contain words such as “expected,” “estimated,” “approximately,” or other similar expressions. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are beyond our control, and in many cases, cannot be predicted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. Factors that could cause actual results to differ materially include, but are not limited to, the level of activity in offshore oil and gas exploration and development, exploration success by producers, operating hazards and delays, risks associated with international operations, actions by customers and other third parties, the fluctuation of current and future prices of oil and gas, the global and regional supply and demand for oil and gas, the intention to scrap certain drilling rigs, the effects of the spread of and mitigation efforts by governments, businesses and individuals related to contagious illnesses, and other factors, including our expectations regarding the timing, completion and anticipated benefits of the proposed business combination with Valaris Limited, an exempted company limited by shares incorporated under the laws of Bermuda, and other risks discussed in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s other filings with the SEC, which are available free of charge on the SEC’s website at: www.sec.gov. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement. We expressly disclaim any obligations or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations or beliefs with regard to the statement or any change in events, conditions or circumstances on which any forward-looking statement is based, except as required by law. All non-GAAP financial measure reconciliations to the most comparative GAAP measure are displayed in quantitative schedules on the Company’s website at www.deepwater.com.

This press release, or referenced documents, do not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and do not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”) or advertising within the meaning of the FinSA. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of Transocean. Investors must rely on their own evaluation of Transocean and its securities, including the merits and risks involved, when making any investment decision involving Transocean securities.

Analyst Contact:
Sarah Davidson
+1 713-232-7217

Media Contact:
Kristina Mays
+1 713-232-7734

Utrecht, 15 September 2026

Aalberts today reports that it has repurchased 75,000 of its own shares in the period from 07 September 2026, up to and including 11 September 2026 for an amount of EUR 3,198,723.74 so at an average share price of EUR 42.65. 

This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase.

Up to and including 11 September 2026, a cumulative total of 1,740,711 shares was repurchased under the share buyback programme for a total consideration of EUR 61,224,458.

Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts.

The share buyback will be executed within the limitations of the authority granted by the Annual General Meeting (AGM) on April 10, 2025. The programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the safe harbour parameters prescribed by the Commission Delegated Regulation 2016/1052 for share buybacks.

Visit aalberts.com/sbb for the weekly progress overview.

Attachment

MIGDAL HAEMEK, Israel, September 15, 2026 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry for high-value analog semiconductor solutions, today announced its participation in upcoming ECOC 2026, taking place September 21–23, 2026 at FYCMA, Malaga, Spain, booth #C1014. During the event days, company representatives will be available for meetings to discuss current and future silicon photonics roadmap.

Tower will showcase its high-volume and high-performance Silicon Photonics platform, widely utilized across the industry for datacenter and telecom optical transceivers, as well as for high-growth applications, including near- and co-packaged optics (NPO/CPO) for next-generation AI cluster architectures, DWDM lasers, optical circuit switching, FMCW LiDAR for Physical AI, and quantum computing. The company will also feature its Silicon Germanium (SiGe) BiCMOS solutions, which complement its SiPho platform to address the higher-bandwidth, lower-latency and lower-power demands of next-generation AI infrastructure.

To learn more about Tower’s advanced silicon photonics (SiPho) platform and RF & HPA technology offerings, visit here.

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, provides technology, development, and process platforms for its customers in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor focuses on creating a positive and sustainable impact on the world through long-term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiPho, SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, displays, and integrated power management (BCD and 700V). Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor currently owns one operating facility in Israel (200mm), two in the U.S. (200mm), and two in Japan (200mm and 300mm) which it owns through its 51% holdings in TPSCo and shares a 300mm facility in Agrate, Italy with STMicroelectronics. For more information, please visit: www.towersemi.com.

Safe Harbor Regarding Forward-Looking Statements
This press release includes forward-looking statements, which are subject to risks and uncertainties. Actual results may vary from those projected or implied by such forward-looking statements. A complete discussion of risks and uncertainties that may affect the accuracy of forward-looking statements included in this press release or which may otherwise affect Tower’s business is included under the heading “Risk Factors” in Tower’s most recent filings on Forms 20-F, F-3, F-4 and 6-K, as were filed with the Securities and Exchange Commission (the “SEC”) and the Israel Securities Authority. Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release. 

                                                ###
Tower Semiconductor Company Contact: Orit Shahar | +972-74-7377440 | oritsha@towersemi.com
Tower Semiconductor Investor Relations Contact: Liat Avraham | +972-4-6506154 | liatavra@towersemi.com

Attachment

  • Iridium Acquisition Now Fully Financed: Rocket Lab completes the $1.944 billion At-The-Market (ATM) equity offering, securing the required cash consideration (alongside available liquidity) to fully fund its pending acquisition of Iridium Communications – expected to close in mid-2027, pending regulatory approvals.
  • Cost-Effective Debt Structure Secured: Iridium amends its existing $1.775 billion credit facility to permit the change of control, establishing long-term, cost-effective permanent financing backed by Iridium’s strong free cash flow and a parent guarantee from Rocket Lab USA.
  • Bridge Facility Terminated: Rocket Lab successfully cancels the initial $3.6B senior secured bridge facility, de-risking the capital structure ahead of the targeted close of the acquisition in mid-2027.

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has successfully completed several critical milestones to fully finance its pending acquisition of Iridium Communications Inc. (“Iridium” and such pending transaction, the “Iridium Acquisition”).

ATM Program Update

Rocket Lab has completed its previously announced At-The-Market share sale (the “ATM Program”), raising approximately $1.944 billion in gross proceeds through the issuance of 29.3 million shares (before commissions and offering expenses).

Rocket Lab intends to use the net proceeds from the ATM Program to fund cash payments under the Iridium Acquisition. If the Company does not consummate the Iridium Acquisition or if it has excess proceeds from the offering of shares under the ATM Program, the Company intends to use the net proceeds to fund future growth, including potential future acquisitions, and for general corporate and working capital purposes.

Change of Control Consent and Amendment for Iridium Existing Credit Agreement

On September 15, 2026, Iridium entered into an amendment (the “Change of Control Amendment”) to its existing term loan facility for its outstanding $1.775 billion term loans (as of June 30, 2026) (the “Iridium Term Loan”) to obtain consent from the requisite lenders to, among other things, amend the definition of “Change of Control” under the credit agreement to carve out Rocket Lab’s pending acquisition of Iridium. As part of the Change of Control Amendment, Rocket Lab USA, Inc., the Company’s primary operating subsidiary and anticipated parent company of Iridium, will provide an unsecured guarantee of the Iridium Term Loan upon the closing of the Iridium Acquisition.

The completion of the Change of Control Amendment will provide Rocket Lab with cost-effective, permanent financing upon the closing of the Iridium Acquisition, supported by Iridium substantial free cash flow.

Termination of Debt Commitment Letter

The Iridium Term Loan, together with the proceeds raised to date under the ATM Program and other unrestricted cash and cash equivalents available to the Company, represent an amount sufficient to pay the required cash consideration, repay certain Iridium indebtedness (other than the Iridium Term Loan) and pay related fees and expenses at the closing of the Iridium Acquisition. In connection with the consummation of the Change of Control Amendment the Company also terminated its $3.6 billion debt commitment for a senior secured debt bridge facility it had entered into in connection with the Iridium Acquisition merger agreement on June 28, 2026. 

The completion of the Change of Control Amendment and the proceeds raised under the ATM Program is another significant milestone in the Company’s pending acquisition of Iridium, which is expected to be completed in mid-2027.

Rocket Lab Investor Relations
investors@rocketlabusa.com

About Rocket Lab

Rocket Lab (Nasdaq: RKLB) is an end-to-end space company delivering rockets, satellites, and spacecraft components for commercial, government, and defense missions. Driven by its industry-leading small-lift rockets Electron and HASTE and its upcoming reusable Neutron medium-lift rocket, Rocket Lab delivers reliable and responsive launch for the world’s most important missions from constellation deployment to missile defense. Rocket Lab’s satellites and components have powered more than 1,700 missions in Earth orbit, as well as deep-space exploration of the Moon, Mars, and beyond. Learn more at www.rocketlabcorp.com.

Additional Information and Where to Find It

This communication is being made in respect of a proposed transaction involving Rocket Lab Corporation (“Rocket Lab”) and Iridium Communications Inc. (“Iridium”). In connection with the proposed transaction, Rocket Lab has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-4 that includes the proxy statement of Iridium that also constitutes a prospectus of Rocket Lab. On August 26, 2026, the Registration Statement was declared effective, Iridium filed the definitive proxy statement, and Rocket Lab filed the final prospectus. The definitive proxy statement/final prospectus was sent to the stockholders of Iridium beginning on or about August 26, 2026, seeking their approval of certain transaction-related proposals. This communication is not a substitute for the definitive proxy statement/final prospectus or any other documents which Rocket Lab or Iridium may file with the SEC in connection with the proposed transaction.

The definitive proxy statement/final prospectus and this communication are not offers to sell any securities, are not soliciting an offer to buy any securities in any state where the offer and sale is not permitted and are not a solicitation of any vote or approval.

ROCKET LAB AND IRIDIUM URGE INVESTORS AND SECURITY HOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4, THE RELATED DEFINITIVE PROXY STATEMENT/FINAL PROSPECTUS INCLUDED THEREIN AND OTHER DOCUMENTS ROCKET LAB AND IRIDIUM FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders can obtain these materials free of charge (when they become available) at the SEC’s website, www.sec.gov. Copies of documents filed with the SEC by Rocket Lab (when they become available) may be obtained free of charge on Rocket Lab’s website at https://investors.rocketlabcorp.com/financial-information/sec-filings or by contacting Rocket Lab’s Investor Relations Department at investors@rocketlabusa.com. Copies of documents filed with the SEC by Iridium (when they become available) may be obtained free of charge on Iridium’s website at https://investor.iridium.com/sec-filings or by contacting Iridium’s Investor Relations Department at investor.relations@iridium.com.

Participants in the Solicitation

Robert H. Niehaus, Louis M. Alterman, Thomas C. Canfield, Matthew J. Desch, Thomas J. Fitzpatrick, L. Anthony Frazier, Suzanne E. McBride, Eric T. Olson, Kay N. Sears, Monique S. Shivanandan and Jacqueline E. Yeaney, all of whom are members of Iridium’s board of directors, and Vincent J. O’Neill, Iridium’s chief financial officer, may be considered participants in Iridium’s solicitation. Information regarding such participants, including their direct or indirect interests, by security holdings or otherwise, is included in the definitive proxy statement/final prospectus filed with the SEC on August 26, 2026. Rocket Lab may also be deemed to be a participant in Iridium’s solicitation; information regarding Rocket Lab is included in the definitive proxy statement/final prospectus filed with the SEC on August 26, 2026. Copies of these documents may be obtained, free of charge, from the SEC or Iridium as described in the preceding paragraph.

Cautionary Note Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements are based on Rocket Lab’s and Iridium’s current expectations, estimates and projections about the proposed transaction and the potential benefits thereof, their respective businesses and industries, management’s beliefs and certain assumptions made by Rocket Lab and Iridium, all of which are subject to change. In this context, forward-looking statements often address expected future events, including future business and financial performance and financial condition. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond our control, and are not guarantees of future results, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof, expectations regarding regulatory approvals, and intentions with respect to financing the transaction. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, or at all, including obtaining stockholder and regulatory approvals and satisfying other conditions to the completion of the transaction; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including the receipt by Iridium of an unsolicited proposal from a third party; (iii) failure to realize the anticipated benefits of the proposed transaction on a timely basis or at all, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, the integration of the businesses of Rocket Lab and Iridium, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of Rocket Lab’s and Iridium’s businesses; (iv) Rocket Lab’s and Iridium’s ability to implement their business strategies; (v) potential litigation relating to the proposed transaction that could be instituted against Rocket Lab, Iridium or their respective directors, managers, or officers, including the effects of any outcomes related thereto; (vi) the risk that disruptions from the proposed transaction will harm Rocket Lab’s or Iridium’s businesses, including current plans and operations, or will otherwise divert management time from ongoing business operations on transaction-related issues; (vii) the ability of Rocket Lab or Iridium to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; (ix) fluctuations in, and uncertainty as to the long-term value of, Rocket Lab or Iridium common stock (including as relating to the risk that any announcements related to the proposed transaction could have adverse effects on the market price of such stock); (x) legislative, regulatory and economic developments affecting Rocket Lab’s and Iridium’s businesses, including actions by government agencies and third parties; (xi) general economic and market developments and conditions, potential changes to international trade relations, geopolitical conflicts and effects from global pandemics, epidemics, or other public health crises; (xii) the evolving legal, regulatory and tax regimes under which Rocket Lab and Iridium operate; (xiii) restrictions during the pendency of the proposed transaction that may impact Rocket Lab’s or Iridium’s ability to pursue certain business opportunities or strategic transactions; (xiv) unexpected costs, charges or expenses resulting from the proposed transaction; (xv) risks that any debt or other financing anticipated in connection with the proposed transaction is not obtained or that such financing cannot be obtained on the anticipated timing or terms or unexpected costs or expenses in connection therewith; and (xvi) the other risks and uncertainties, as described in the periodic reports that Rocket Lab and Iridium file with the SEC. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the definitive proxy statement/final prospectus filed with the SEC on August 26, 2026 in connection with the proposed transaction. Neither Rocket Lab nor Iridium assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Forward-looking statements included in this communication are made as of the date of this communication.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.